Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Magnasense

0.041

 

SEK

 

-19.37 %

Less than 1K followers

MAGNA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
-19.37%
-52.53%
+74.48%
+243.21%
+154.75%
-47.24%
-97.93%
-
-96.76%

Magnasense operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and mainly includes drugs for the treatment of multiple sclerosis. In addition to the main business, associated ancillary services are offered. The business is run in collaboration with other pharmaceutical actors, where the largest presence is found in the Nordic region.

Read more
Market cap
50.34M SEK
Turnover
295.8K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
30/6
2025

General meeting '25

29/8
2025

Interim report Q2'25

31/3
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release5/28/2025, 6:58 AM

Magnasense beslutar om riktad emission av units till garant i samband med genomförd företrädesemission

Magnasense
Regulatory press release5/28/2025, 6:58 AM

Magnasense resolves on directed issue of units to guarantor in connection with completed rights issue

Magnasense
Regulatory press release5/27/2025, 7:00 AM

Kallelse till årsstämma i Magnasense AB (publ)

Magnasense

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/27/2025, 7:00 AM

Notice of Annual General Meeting in Magnasense AB (publ)

Magnasense
Regulatory press release5/26/2025, 10:47 AM

Magnasenses företrädesemission har registrerats – omvandling av betalda tecknade units (BTU) samt första dag för handel med teckningsoptioner av serie TO 5 och TO 6

Magnasense
Regulatory press release5/26/2025, 10:47 AM

Magnasense’s rights issue has been registered – conversion of paid subscribed units (BTU) and first day of trading in warrants of series TO 5 and TO 6

Magnasense
Regulatory press release5/12/2025, 9:00 PM

Magnasense announces outcome in rights issue of units

Magnasense
Regulatory press release5/12/2025, 9:00 PM

Magnasense offentliggör utfall i företrädesemission av units

Magnasense
Press release5/6/2025, 6:30 AM

Magnasense Advances Saliva-Based Diagnostics Breakthrough with Partially Secured, Ongoing Rights Issue – Investors Welcome to Participate Until 8 May 2025

Magnasense
Press release5/5/2025, 9:43 AM

Interview with Magnasense: Key Insights from the RADx Initiative

Magnasense
Press release5/1/2025, 8:32 AM

Magnasense and Salignostics Successfully Complete Feasibility Study

Magnasense
Regulatory press release4/29/2025, 9:44 PM

Magnasense erhåller ytterligare garantiåtaganden om totalt cirka 8,8 MSEK i pågående företrädesemission av units – lägstanivån som krävs för emissionens genomförande är säkerställd

Magnasense
Regulatory press release4/29/2025, 9:44 PM

Magnasense receives additional guarantee commitments totalling approx. MSEK 8.8 in ongoing rights issue of units - the minimum level required for the completion of the issue is secured

Magnasense
Press release4/28/2025, 7:47 AM

Magnasense AB Targets Gum Disease Market with Groundbreaking Diagnostic Technology — Capital Raise Underway to Accelerate Entry in High-Value Underserved Market

Magnasense
Press release4/25/2025, 8:00 AM

Aegirbio UK Ltd and Undisclosed Partner Sign LOI to Develop Innovative Digital Diagnostic Product

Magnasense
Press release4/24/2025, 10:30 AM

Overview of the Rights Issue in Magnasense AB

Magnasense
Regulatory press release4/24/2025, 7:07 AM

The subscription period in Magnasense's rights issue of units begins today

Magnasense
Regulatory press release4/24/2025, 7:07 AM

Teckningsperioden i Magnasenses företrädesemission av units inleds idag

Magnasense
Press release4/23/2025, 7:00 AM

Interview with Michael Schwartz, board member at Magnasense AB

Magnasense
Press release4/22/2025, 2:02 PM

Magnasense AB Develops Innovative Saliva Test for Gum Disease Detection

Magnasense
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team